Longitudinal high-dimensional analysis identifies immune features associating with response to anti-PD-1 immunotherapy

Elaine Lai-Han Leung (), Run-Ze Li, Xing-Xing Fan, Lily Yan Wang, Yan Wang, Zebo Jiang, Jumin Huang, Hu-Dan Pan, Yue Fan, Hongmei Xu, Feng Wang, Haopeng Rui, Piu Wong, Hermi Sumatoh, Michael Fehlings, Alessandra Nardin, Paul Gavine, Longen Zhou, Yabing Cao () and Liang Liu ()
Additional contact information
Elaine Lai-Han Leung: Cancer Center, Faculty of Health Sciences; MOE Frontiers Science Center for Precision Oncology, University of Macau
Run-Ze Li: The Second Affiliated Hospital of Guangzhou University of Chinese Medicine (Guangdong Provincial Hospital of Chinese Medicine)
Xing-Xing Fan: Macau University of Science and Technology
Lily Yan Wang: Janssen Research & Development
Yan Wang: Merck Sharp & Dohme
Zebo Jiang: Macau University of Science and Technology
Jumin Huang: Macau University of Science and Technology
Hu-Dan Pan: The Second Affiliated Hospital of Guangzhou University of Chinese Medicine (Guangdong Provincial Hospital of Chinese Medicine)
Yue Fan: Janssen Research & Development
Hongmei Xu: Janssen Research & Development
Feng Wang: Janssen Research & Development
Haopeng Rui: Janssen Research & Development
Piu Wong: HiFiBio Therapeutics
Hermi Sumatoh: ImmunoScape
Michael Fehlings: ImmunoScape
Alessandra Nardin: ImmunoScape
Paul Gavine: Janssen Research & Development
Longen Zhou: Janssen Research & Development
Yabing Cao: Kiang Wu Hospital
Liang Liu: The Second Affiliated Hospital of Guangzhou University of Chinese Medicine (Guangdong Provincial Hospital of Chinese Medicine)

Nature Communications, 2023, vol. 14, issue 1, 1-9

Abstract: Abstract Response to immunotherapy widely varies among cancer patients and identification of parameters associating with favourable outcome is of great interest. Here we show longitudinal monitoring of peripheral blood samples of non-small cell lung cancer (NSCLC) patients undergoing anti-PD1 therapy by high-dimensional cytometry by time of flight (CyTOF) and Meso Scale Discovery (MSD) multi-cytokines measurements. We find that higher proportions of circulating CD8+ and of CD8+CD101hiTIM3+ (CCT T) subsets significantly correlate with poor clinical response to immune therapy. Consistently, CD8+ T cells and CCT T cell frequencies remain low in most responders during the entire multi-cycle treatment regimen; and higher killer cell lectin-like receptor subfamily G, member 1 (KLRG1) expression in CCT T cells at baseline associates with prolonged progression free survival. Upon in vitro stimulation, CCT T cells of responders produce significantly higher levels of cytokines, including IL-1β, IL-2, IL-8, IL-22 and MCP-1, than of non-responders. Overall, our results provide insights into the longitudinal immunological landscape underpinning favourable response to immune checkpoint blockade therapy in lung cancer patients.

Date: 2023
References: View references in EconPapers View complete reference list from CitEc
Citations:

Downloads: (external link)
https://www.nature.com/articles/s41467-023-40631-0 Abstract (text/html)

Related works:
This item may be available elsewhere in EconPapers: Search for items with the same title.

Export reference: BibTeX RIS (EndNote, ProCite, RefMan) HTML/Text

Persistent link: https://EconPapers.repec.org/RePEc:nat:natcom:v:14:y:2023:i:1:d:10.1038_s41467-023-40631-0

Ordering information: This journal article can be ordered from
https://www.nature.com/ncomms/

DOI: 10.1038/s41467-023-40631-0

Access Statistics for this article

Nature Communications is currently edited by Nathalie Le Bot, Enda Bergin and Fiona Gillespie

More articles in Nature Communications from Nature
Bibliographic data for series maintained by Sonal Shukla () and Springer Nature Abstracting and Indexing ().